THROMBOPOIETIN IN NEONATAL THROMBOCYTOPENIA

血小板减少症在患病新生儿中相对常见。在早产时 婴儿可与脓毒症等临床实体相关， 先兆子痫母亲的生长迟缓婴儿和 在产程中窒息。有一种假设是，患有 这些临床症状可能会发展为新生儿血小板减少症 暂时性的TPO缺陷正在这里进行调查。如果找到了这个 说实话，这些情况可以用来治疗。 重组人血小板生成素，即将用于 初步的临床试验。这项研究的目的是检验和量化 血小板减少性新生儿的血小板生成素水平 状态：科目注册和数据分析已完成。

Thrombocytopenia is relatively common in sick newborn infants. In preterm infants it can occur in association with such clinical entities as sepsis, growth retarded infants of mothers with pre-eclampsia and infants who suffered from intrapartum asphyxia. The hypothesis that infants with these clinical conditions may develop neonatal thrombocytopenia from a temporary deficiency of TPO is under investigation here. If this is found to be true, these conditions would be amenable to treatment with recombinant human thrombopoietin, which will soon become available for initial clinical trials. The aim of this study is to examine and quantify thrombopoietin levels in thrombocytopenic newborns. Status: Subject enrollment and data analysis completed.